Jangsu

This research aims to perform molecular screening for patients with relapsed small cell lung cancer or neuroendocrine carcinoma. It is not a drug treatment study but seeks to identify molecular profiles that may help determine eligibility for future drug intervention studies within the SUKSES trial. This screening can be done before, during, or after the initial treatment. The study involves analyzing tumor tissues, either fresh or archival, using advanced molecular techniques such as NGS-based cancer panels, Nanostring CNV, immunohistochemistry, and FISH. DNA will be extracted from both tissue samples and blood. Blood samples will be collected at baseline, three weeks, six weeks, twelve weeks, and during subsequent imaging visits. The specific laboratory methods will be standardized and guided by pathologists. Participants will provide tissue and blood samples, and their tumor molecular subtypes will be assessed as the primary outcome. Pathologists will perform detailed molecular analyses to understand tumor characteristics. The study monitors changes over time through several blood collections and imaging, with no drug treatments included. The total duration and follow-up depend on participant schedules for imaging and sample collection.